Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | FPR1 | P21462 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29343956 | 0.87 | FPR1 (0.39) | MAPTLMNATP53P2RY12MEN1 | |
| SCHEMBL29342738 | 0.86 | ADRB2 (0.38) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL29222044 | 0.84 | SMN1; SMN2 (0.46) | LMNATP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29340215 | 0.82 | MTNR1A (0.39) | MEN1KMT2AHTTFPR1ALDH1A1 | |
| SCHEMBL29343980 | 0.80 | EED (0.41) | EEDMAPTLMNATP53P2RY12 | |
| SCHEMBL29340216 | 0.78 | ADCY10 (0.40) | LMNAHTTFPR1ALDH1A1 | |
| SCHEMBL29343015 | 0.74 | KMT2A (0.36) | EEDMAPTLMNANPC1RAB9A | |
| SCHEMBL15509273 | 0.74 | NPC1 (0.43) | MAPTLMNATP53NPC1RAB9A | |
| SCHEMBL27163469 | 0.74 | KDM4E (0.45) | EEDMAPTLMNATP53NPC1 | |
| SCHEMBL17162371 | 0.74 | ADORA3 (0.44) | LMNANPC1RAB9AKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | EED 4841/4885MAPT 506/4885LMNA 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.